Novartis (VTX:NOVN) has been assigned a CHF 85 target price by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday, April 17th, Borsen Zeitung reports. The brokerage currently has a “sell” rating on the stock.
A number of other equities analysts also recently issued reports on NOVN. Morgan Stanley set a CHF 80 price target on Novartis and gave the stock a “sell” rating in a research report on Wednesday, April 10th. Deutsche Bank set a CHF 96 price target on Novartis and gave the stock a “neutral” rating in a research report on Friday, January 11th. Credit Suisse Group set a CHF 84 price target on Novartis and gave the stock a “neutral” rating in a research report on Friday, April 5th. HSBC set a CHF 86 price target on Novartis and gave the stock a “neutral” rating in a research report on Wednesday, February 6th. Finally, Goldman Sachs Group set a CHF 110 price target on Novartis and gave the stock a “buy” rating in a research report on Thursday, January 24th. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 88.29.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Resistance Level
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.